About the Program
In 2002, Bayer HealthCare instituted the Bayer Hemophilia Awards Program with the following mission:
The Bayer Hemophilia Awards Program supports basic and clinical research and education in hemophilia. Through grants provided to early career investigators, fellows in training, and other hemophilia care professionals, the program seeks to support the next steps for the next generation of care and treatment options for people with hemophilia worldwide.
Who We Are
The Bayer Group is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG, with annual sales of EUR 16,913 million (2010), is one of the world’s leading, innovative companies in the health care and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare’s aim is to discover and manufacture products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 53,400 employees and is represented in more than 100 countries.
Bayer envisions the Hemophilia Awards Program as a step toward making the dream of hemophilia cures and improved treatments a reality.
The Bayer Hemophilia Awards Program demonstrates our commitment to the global bleeding disorders community and to advancing the state of the art of hemophilia care.
Currently, the Program’s Research Priorities are focused on hemophilia. The program’s research priorities for the 2015/2016 cycle are as follows:
- Patient-related, e.g. comorbidities, inhibitors, joint disease
- Treatment-related, e.g. new products, regimens, gene therapy
- Mechanistic, e.g. molecular mechanisms, experimental models
- Outcomes research, e.g. patient-reported outcomes, quality of life
In previous award cycles the Program has provided funding to support several projects in the following areas:
- Aspects of the molecular biology of vWF structure and function and the diagnosis and treatment of vWD
- The function and regulation of platelets and the diagnosis of platelet disorders.
As a result, the Program will not award projects in these areas during this award cycle.
Excluded Research Topics
In order to maintain a focus on hemophilia and bleeding disorders, the Program will not support research focused on:
- Products or technologies licensed or patented by competitors of Bayer
- Cancer diagnosis or therapy
- AIDS diagnosis or hepatitis therapy except where specifically related to patients with hemophilia and HIV, HCV or HBV
- Cardiovascular disease diagnosis or therapy
- Purely thrombotic disorders.
Dates & Deadlines
Thank you for your interest in applying for the Bayer Hemophilia Awards Program. This program represents Bayer’s continuing commitment to taking the next steps for the next generation of people with hemophilia to enjoy a better quality of life and treatment options.
Applications will be processed solely through the Internet and all applications must be submitted in English.
As a first step, applicants should submit a Letter of Intent describing the proposed project in 500 words or fewer. All Letters of Intent submitted will receive an e-mail confirming receipt.
Letters of Intent (LOI) will be reviewed by all 13 members of the Grants Review and Awards Committee. In some cases, additional information may be requested.
Selected applicants will be invited to submit a full proposal that will be reviewed by at least two members of the Grants Review and Awards Committee. These applicants will be e-mailed a full application form.
The results of the review process and funding decisions will be communicated to applicants in May each year. Funded applicants must send a letter of acceptance and enter into an agreement outlining obligations and understandings prior to disbursement of funds.
Awardees will be invited to attend an Awards Dinner that will coincide with the bi-annual meetings of the World Federation of Hemophilia (WFH) or the International Society for Thrombosis and Hemostasis (ISTH).
The table below summarizes the application timelines for 2016/17.
|LOI submissions||Permitted throughout the year|
|Deadline for LOI consideration||November 30,2016|
|GRAC reviews LOIs||December 2016 / January 2017|
|GRAC informs applicants||January 31, 2017|
|Applicants develop Full Proposals||February/March 2017|
|Full Proposals submitted||March 2017|
|GRAC reviews Full Proposals||April/May 2017|
|Applicants notified of GRAC decisions||May/June 2017|
|Funding available||July/August 2017|
Letters of Intent and Full Applications are reviewed by the Grants Review and Awards Committee which comprises 14 members, representing many of the leading experts from clinical and academic medicine:
- Alok Srivastava MD, Vellore, India (chairman)
- Valder Arruda MD, Philadelphia, USA
- Marijke van den Berg MD, Utrecht, Netherlands
- Kate Khair PhD, London, UK
- Craig Kessler MD, Washington DC, USA
- Riitta Lassila MD, Helsinki, Finland
- David Lillicrap MD, Kingston, Canada
- Pier Mannucci MD, Milan, Italy
- Amit Nathwani MD, London, UK
- Michael Nichol PhD, Los Angeles, CA, USA
- Johannes Oldenburg MD, Bonn, Germany
- Brenda Riske MS, MBA, MPA, Aurora, CO, USA
- Midori Shima MD, Nara, Japan
- Gil White MD, Milwaukee, WI, USA
All members of the Grants Review and Awards Committee will review the Letters of Intent and determine which candidates will be invited to submit full applications. Full applications will be reviewed by at least two members of the committee.
Reviewers will evaluate full applications according to the criteria outlined in the Awards section of this website. The reviewers will provide written comments and preliminary numeric scores according to these criteria.
The Committee will meet to discuss individual proposals including strengths, weaknesses and scoring. In this meeting, a consensus score for each grant application will be agreed upon. Proposals will then be ranked according to these scores in order to determine funding. In the event of identical scoring, the Committee will discuss the proposals in question and revise the scoring in order to clearly define a ranked priority. Funding will occur on a regional basis.
Three regions are defined as:
- United States and Canada
- Europe (for the purposes of this award, the Europe region includes Austria, Belgium, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Luxembourg, Netherlands, Norway, Portugal, Spain, Sweden, Switzerland, United Kingdom)
- Japan, China, India, Australia and all other countries.
Awards will be determined on the final priority score as agreed by the Grants Review and Awards Committee. In the event that inadequate numbers of acceptable applications are received from a particular region, additional acceptable proposals will be funded solely on the basis of priority scores, without regard to region.
The Committee’s decision is final and there is no appeal mechanism. Applicants who have constructive suggestions about the review of their applications, or the process in general, are encouraged to contact us. See Contact.
Conflict of Interest
The Program has ‘conflict of interest’ guidelines that ensure reviews are conducted in a fair and equitable manner. Reviewers will not participate in the review or priority scoring of applications in which they, or institutions with which they are affiliated, have an interest. Also, to the extent practicable, reviewers will not participate in the review of proposals competing for funding with proposals for individuals associated with their institutions.
The members of the Grants Review and Awards Committee are bound by the confidentiality rules generally applicable to such bodies.
Current Award Recipients: 2016
Fellowship Project Award
Dr Maria Fasulo
Angelo Bianchi Bonomi Hemophilia And Thrombosis Center, Milan, Italy
Assessing the development of early signs of joint damage in relation to the start of replacement therapy and the age at first joint bleed in children with severe and moderately severe hemophilia.
Dr Martin Scott
Manchester Haemophila Comprehensive Care Centre, Department of Clinical Haematology, UK
The use of a National database and patient reporting tool to determine 'real-world' outcomes of patients with congenital haemophilia using prophylactic factor replacement.
Dr David Stelzeneder
Medical University of Vienna, Austria
Investigating the links between microbleed events, joint degeneration and synovitis, to aid therapeutic planning in patients with bleeding disorders.
Early Career Investigator Award
Dr Moanaro Biswas
University of Florida, Cancer & Genetics Research Center, Gainesville, FL, USA
T cell therapy against factor VIII inhibitors
Dr Maurizio Tomaiuolo
University of Pennsylvania, PA, USA
The platelet aggregate nanoanatomy and coagulation factors concentration mediate thrombin formation
Dr James Dahlman
Georgia Institute of Technology
A high throughput in vivo screen for targeted hemophilia gene therapy delivery systems
Dr Anja Schmidt
Goethe University, Frankfurt, Germany
FVIII-specific regulatory T cells for tolerance induction obtained by expansion and phenotypic modulation of FVIII-specific naïve T cells
Special Project Award
Dr Michael Milone
University of Pennsylvania, PA, USA
Novel strategy to edradicate FVIII inhibitors by chimeric allo-antigen receptors
Dr Gary Gilbert
Boston VA Research Instittute, MA, USA
Platelet-dependent activity of factor VIII in mild and moderate hemophilia A
Dr Marie-Christine Bouton
INSERM DR Paris VII, France
Inhibition of protease nexin-1 (PN-1) as a promising antibleeding strategy in haemophilia
Dr Yasuaki Shida
The Department of Pediatrics, Nara Medical University, Japan
The role of shear stress on biosynthesis and interaction of factor VIII and von Willebrand factor
Julia Hews-Girard & Amanda Zahariuk
Southern Alberta Rare Blood and Bleeding Disorders Comprehensive Care Program, Foothills Medical Center, Calgary, AB, Canada
Use of self-report and accelerometry to assess kinesiophobia, physical activity and quality of life of adult males with hemophilia in a single canadian HTC
Dr Liesbeth Schrijvers
Van Creveidkliniek, University Medical Center, Utrecht, the Netherlands
Why is adherence so low? Exploring patient needs and drivers of adherence and self-management
Dr Ruben Cuesta
Royal Foundation Victoria Eugenia, Instituto de Salud Carlos, Madrid, Spain
Effectiveness and safety of myofascial therapy in hemophilic arthropathy
Dr Elvira Correa
IHTC “Cláudio Luiz Pizzigatti Correa” - Hematology and Hemotherapy Blood Transfusion Center, University of Campinas, Brazil
Local vs systemic use of tranexamic acid in patients with bleeding disorders undergoing oral surgery
Outcomes Research Award
Dr John Bentley
School of Pharmacy, University of Mississippi, MS, USA
Health Utility and its determinants among children with hemophilia